The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
By a multiplicity of mechanisms, hypoxia and acidosis create a nurturing environment for tumor progression and the evolution of metastatic, drug-resistant cells. Acidosis drives mutagenesis and promotes the subversion of checkpoints and apoptotic mechanisms. Hypoxic tissues secrete cytokines that undermine normal anti-tumor surveillance by macrophages, turning them into accomplices and facilitators of invasion and angiogenesis. Invasiveness is also abetted by acidosis, the result of shifting to an anaerobic glycolytic metabolism. These factors explain the generally poor prognosis indicated by tumors expressing hypoxia-inducible factor-1 (HIF-1). However, these insights into the physiology of hypoxic tumors have inspired the development of new chemotherapeutic approaches directed at these tissues, including bioreductive drugs and gene therapies, some of which are in clinical trials. The ability to target the hypoxic compartment should allow longer progression-free survival and overall survival of patients bearing solid tumor malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
RetractedHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“The hypoxia inducible transcription factor-1 (HIF-1) is considered to be a crucial mediator of cell response to reduced oxygen levels (30, 83).”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“This program is foiled when p53 is mutant (62).”
BackgroundBingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022 · cited 3×
“TAMs exposed to hypoxia acquire a pro- angiogenic phenotype by expressing vascular endothelial growth factor (VEGF) and become pro-invasive through increased expression of proteinases such as matrix metalloproteinase-7 (MMP-7) (20, 25-28).”
BackgroundFantin, V. R., St-Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.023 · Cited by 1,635 · cited 4×
“Overexpression of any of these genes leads to increased glycolysis in tumors (74, 75, 76, 85).”
BackgroundInfluentialAsparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558 · cited 2×
“2 FIH Under normoxic conditions, an asparagine (located at N(803) in HIF-1 alpha and N(851) in HIF-2 alpha) is hydroxylated by cofactors 2-oxoglutarate, oxygen and the enzyme FIH-1 (Fe dependent HIF- alpha asparagine hydroxylase) (7, 95).”
BackgroundDimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1
Jiang, B.-H., Rue, E., Wang, G. L., Roe, R., & Semenza, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17771 · Cited by 1,106 · cited 1×
“DNA binding is mediated by the bHLH domains, while the two PAS domains are required for heterodimer formation (86, 89).”
BackgroundRegulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967 · cited 2×
“Binding of MDM2-p53 to HIF-1 alpha causes HIF-1 alpha to become ubiquinated and degraded (97).”
BackgroundAcid-Mediated Tumor Invasion: a Multidisciplinary Study
Gatenby, R. A., Gawlinski, E. T., Gmitro, A. F., Kaylor, B., & Gillies, R. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4193 · Cited by 771 · cited 1×
“Once the basement membrane is breached, cancer cells are able to invade the surrounding tissue (82).”
BackgroundTumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
Bos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H. M., Semenza, G. L., van Diest, P. J., & van der Wall, E. (2003) · Cancer · doi:10.1002/cncr.11246 · Cited by 500 · cited 1×
“in 2001 found a crucial role for HIF-1 in breast cancer progression (48, 103).”
BackgroundGiatromanolaki, A., Koukourakis, M. I., Sivridis, E., Turley, H., Talks, K., Pezzella, F., Gatter, K. C., & Harris, A. L. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2018 · Cited by 478 · cited 1×
“Hypoxia induces the upregulation of angiogenic factors such as VEGF (vascular endothelial growth factor), ANG2 (angiopoeitin2), PDGF (platelet derived growth factor), PLGF (placenta growth factor), TGF (transforming growth factors), IL-8 and HGF (hepatocyte growth factor) (51).”
BackgroundGradin, K., McGuire, J., Wenger, R. H., Kvietikova, I., Whitelaw, M. L., Toftgård, R., Tora, L., Gassmann, M., & Poellinger, L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5221 · Cited by 470
HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression
Koshiji, M., To, K. K.-W., Hammer, S., Kumamoto, K., Harris, A. L., Modrich, P., & Huang, L. E. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.015 · Cited by 346
Cited by
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Song, X., Feng, L., Liang, C., Yang, K., & Liu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02365 · Cited by 581
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Endothelial Cell Metabolism in Health and Disease
Rohlenova, K., Veys, K., Miranda-Santos, I., De Bock, K., & Carmeliet, P. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.010 · Cited by 335
Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise
Betof, A. S., Lascola, C. D., Weitzel, D., Landon, C., Scarbrough, P. M., Devi, G. R., Palmer, G., Jones, L. W., & Dewhirst, M. W. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv040 · Cited by 309
“JNCI J Natl Cancer Inst (2015) 107(5): djv040”
Metadata
- Authors
- DeClerck, K.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2010
- Volume
- 15
- Issue
- 1
- Pages
- 213
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/3616
- OpenAlex
- W1989616606
- Cited by
- 109
- References
- 14
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.